Clinical trials sponsored by Essen Biotech

Phase breakdown

Conditions studied

Recruiting trials led by Essen Biotech

• Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
  NCT07410494 · Phase: Phase 1, Phase 2 · Ages: 8 Years to 85 Years · Sex: All (male and female) · 3 locations
• EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
  NCT07410676 · Phase: Phase 1, Phase 2 · Ages: No age limits stated · Sex: All (male and female) · 1 location
• Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
  NCT06350110 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 90 Years · Sex: All (male and female) · 1 location
• Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease
  NCT06399107 · Phase: Phase 1, Phase 2 · Ages: 2 Years to 90 Years · Sex: All (male and female) · 1 location
• Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer
  NCT07066995 · Phase: Phase 1, Phase 2 · Ages: 21 Years to 90 Years · Sex: All (male and female) · 1 location
• Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases
  NCT06428188 · Phase: Phase 1, Phase 2 · Ages: 21 Years to 90 Years · Sex: All (male and female) · 1 location
• TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
  NCT06538012 · Phase: Phase 1, Phase 2 · Ages: 16 Years to 90 Years · Sex: All (male and female) · 1 location
• TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer
  NCT06532799 · Phase: Phase 1, Phase 2 · Ages: 16 Years to 90 Years · Sex: All (male and female) · 1 location

Common questions

How many trials is Essen Biotech recruiting for?

Essen Biotech is the lead sponsor of 8 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.